Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronan Roussel

Showing results (1-10 of 202) with videos related to

Pageof 21
Sort By:
Circulation|January 8, 2019
Letter by Potier and Roussel Regarding Article, "Are We Ready to Bell the Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes"Louis Potier, Ronan Roussel
Circulation|August 24, 2016
Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications: A Worthwhile Effort?Philippe Gabriel Steg, Ronan Roussel
JAMA Cardiology|February 2, 2022
Hypertriglyceridemia in the MESA StudyBoris Hansel, Ronan Roussel, Philippe Giral
Lancet (London, England)|May 5, 2018
Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?Boris Hansel, Ronan Roussel, Philippe Giral
The New England Journal of Medicine|July 7, 2009
Glucose control in critically ill patientsKamel Mohammedi, Ronan Roussel, Michel Marre
American Journal of Physiology. Renal Physiology|May 1, 2015
Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and ureaLise Bankir, Ronan Roussel, Nadine Bouby
Current Opinion in Nephrology and Hypertension|April 14, 2017
Vasopressin and diabetic nephropathyRonan Roussel, Gilberto Velho, Lise Bankir
Lancet (London, England)|April 27, 2010
Survival as a function of HbA(1c) in people with type 2 diabetesJean-Pierre Riveline, Ronan Roussel, Kamel Mohammedi
Cardiovascular Diabetology|May 14, 2021
SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesisLouis Potier, Kamel Mohammedi, Gilberto Velho, et al.
Diabetes/Metabolism Research and Reviews|April 22, 2020
Insulin glargine 300 U/mL and insulin degludec: A review of the current evidence comparing these two second-generation basal insulin analoguesAlice Cheng, Timothy S Bailey, Didac Mauricio, et al.
Pageof 21

Showing results (1-10 of 202) with videos related to

Sort By:
Pageof 21
Circulation|January 8, 2019
Letter by Potier and Roussel Regarding Article, "Are We Ready to Bell the Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes"Louis Potier, Ronan Roussel
Circulation|August 24, 2016
Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications: A Worthwhile Effort?Philippe Gabriel Steg, Ronan Roussel
JAMA Cardiology|February 2, 2022
Hypertriglyceridemia in the MESA StudyBoris Hansel, Ronan Roussel, Philippe Giral
Lancet (London, England)|May 5, 2018
Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?Boris Hansel, Ronan Roussel, Philippe Giral
The New England Journal of Medicine|July 7, 2009
Glucose control in critically ill patientsKamel Mohammedi, Ronan Roussel, Michel Marre
American Journal of Physiology. Renal Physiology|May 1, 2015
Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and ureaLise Bankir, Ronan Roussel, Nadine Bouby
Current Opinion in Nephrology and Hypertension|April 14, 2017
Vasopressin and diabetic nephropathyRonan Roussel, Gilberto Velho, Lise Bankir
Lancet (London, England)|April 27, 2010
Survival as a function of HbA(1c) in people with type 2 diabetesJean-Pierre Riveline, Ronan Roussel, Kamel Mohammedi
Cardiovascular Diabetology|May 14, 2021
SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesisLouis Potier, Kamel Mohammedi, Gilberto Velho, et al.
Diabetes/Metabolism Research and Reviews|April 22, 2020
Insulin glargine 300 U/mL and insulin degludec: A review of the current evidence comparing these two second-generation basal insulin analoguesAlice Cheng, Timothy S Bailey, Didac Mauricio, et al.
Pageof 21